Trial · NCT04517864
Results by group309
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 309
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in I-V Interwave Latency on Brainstem Auditory Evoked Potentials (BAEP) at a Stimulus Intensity of 80 Decibels (dB) From the Right Side at Month 9 | Ritlecitinib 200/50 mg QD | 0.011 | 95% Confidence Interval -0.043 to 0.065 | Millisecond (ms) | |
| Change From Baseline in I-V Interwave Latency on Brainstem Auditory Evoked Potentials (BAEP) at a Stimulus Intensity of 80 Decibels (dB) From the Right Side at Month 9 | Placebo | -0.010 | 95% Confidence Interval -0.063 to 0.043 | Millisecond (ms) | |
| Change From Baseline in I-V Interwave Latency on BAEP at a Stimulus Intensity of 80 dB From the Left Side at Month 9 | Ritlecitinib 200/50 mg QD | 0.031 | 95% Confidence Interval -0.012 to 0.075 | ms | |
| Change From Baseline in I-V Interwave Latency on BAEP at a Stimulus Intensity of 80 dB From the Left Side at Month 9 | Placebo | 0.022 | 95% Confidence Interval -0.020 to 0.065 | ms | |
| Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Right Side at Month 6 | Ritlecitinib 200/50 mg QD | -0.030 | 95% Confidence Interval -0.072 to 0.011 | millisecond (ms) | |
| Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Right Side at Month 6 | Placebo | -0.024 | 95% Confidence Interval -0.065 to 0.017 | millisecond (ms) | |
| Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Right Side at Month 9E and 15E | Ritlecitinib 200/50/50 mg QD | Month 9E (Month 9 in the Active Therapy Extension Phase) | 0.010 | Standard Deviation 0.1233 | millisecond (ms) |
| Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Right Side at Month 9E and 15E | Placebo -> Ritlecitinib 200/50 mg QD | Month 9E (Month 9 in the Active Therapy Extension Phase) | -0.033 | Standard Deviation 0.2448 | millisecond (ms) |
| Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Right Side at Month 9E and 15E | Ritlecitinib 200/50/50 mg QD | Month 15E (Month 15 in the Active Therapy Extension Phase) | 0.051 | Standard Deviation 0.1188 | millisecond (ms) |
| Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Right Side at Month 9E and 15E | Placebo -> Ritlecitinib 200/50 mg QD | Month 15E (Month 15 in the Active Therapy Extension Phase) | 0.034 | Standard Deviation 0.2224 | millisecond (ms) |
| Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Left Side at Month 6 | Ritlecitinib 200/50 mg QD | 0.021 | 95% Confidence Interval -0.011 to 0.054 | millisecond (ms) | |
| Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Left Side at Month 6 | Placebo | -0.020 | 95% Confidence Interval -0.053 to 0.012 | millisecond (ms) | |
| Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Left Side at Month 9E and 15E | Ritlecitinib 200/50/50 mg QD | Month 9E (Month 9 in the Active Therapy Extension Phase) | 0.006 | Standard Deviation 0.1109 | millisecond (ms) |
| Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Left Side at Month 9E and 15E | Placebo -> Ritlecitinib 200/50 mg QD | Month 9E (Month 9 in the Active Therapy Extension Phase) | 0.056 | Standard Deviation 0.1694 | millisecond (ms) |
| Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Left Side at Month 9E and 15E | Ritlecitinib 200/50/50 mg QD | Month 15E (Month 15 in the Active Therapy Extension Phase) | 0.024 | Standard Deviation 0.1044 | millisecond (ms) |
| Change From Baseline in I-V Interwave Latency on BAEP at 80 dB From the Left Side at Month 9E and 15E | Placebo -> Ritlecitinib 200/50 mg QD | Month 15E (Month 15 in the Active Therapy Extension Phase) | 0.017 | Standard Deviation 0.2339 | millisecond (ms) |
| Change From Baseline in Percentage of Intraepidermal Nerve Fiber (IENF) With Axonal Swelling in Skin Punch Biopsies at Month 9 | Ritlecitinib 200/50 mg QD | 0.0 | Inter-Quartile Range -0.5 to 2.5 | Percentage of Nerve Fibers | |
| Change From Baseline in Percentage of Intraepidermal Nerve Fiber (IENF) With Axonal Swelling in Skin Punch Biopsies at Month 9 | Placebo | 0.0 | Inter-Quartile Range -2.0 to 1.0 | Percentage of Nerve Fibers | |
| Change From Baseline in Percentage of IENFs With Axonal Swelling in Skin Punch Biopsies at Month 15E | Ritlecitinib 200/50/50 mg QD | 0 | Inter-Quartile Range -1.0 to 0 | Percentage of Nerve Fibers | |
| Change From Baseline in Percentage of IENFs With Axonal Swelling in Skin Punch Biopsies at Month 15E | Placebo -> Ritlecitinib 200/50 mg QD | 0 | Inter-Quartile Range -1.0 to 0 | Percentage of Nerve Fibers |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04517864/results